Crizotinib    (DrugBank: Crizotinib)

1 disease
IDDisease name (Link within this page)Number of trials
34Neurofibromatosis1

34. Neurofibromatosis    [ 120 clinical trials,   182 drugs,   (DrugBank: 72 drugs),   84 drug target genes,   194 drug target pathways]
Searched query = "Neurofibromatosis", "NF1", "von Recklinghausen disease", "NF2"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 120 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04283669
(ClinicalTrials.gov)
February 18, 202022/2/2020Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular SchwannomasOpen-label, Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular SchwannomasNeurofibromatosis 2;Progressive Vestibular Schwannoma (VS)Drug: CrizotinibUniversity of Alabama at BirminghamMemorial Sloan Kettering Cancer CenterRecruiting6 YearsN/AAll19Phase 2United States